EA1181: (CompassHER2 pCR) Preoperative THP and postoperative HP in patients who achieve a pathologic complete response.

Part 1 Component of: The CompassHER2 Trials (COMprehensive use of Pathologic response ASSessment to optimize therapy in HER2-positive breast cancer)

NCT# 04266249

Description: This study is being done to evaluate the effect of decreasing chemotherapy in patients with breast cancer without evidence of remaining cancer after receiving pre-surgery chemotherapy and HER2-targeted therapy without compromising long-term survival.

Learn more about the EA1181 trial or call Phoenixville Hospital Research Office at 610-983-1811.

Alliance-A011801: The CompassHER2 trials (COMprehensive use of Pathologic Response ASSessment to optimize therapy in HER2-positive breast cancer): CompassHER2 Residual Disease (RD), a double-blinded, phase III randomized trial of T-DM1 and placebo compared with T-DM1 and tucatinib.

The purpose of this study is to compare the usual treatment with T-DM1 alone to T-DM1 plus tucatinib.

Learn more about the Alliance-A011801 trial or call the Reading Hospital Protocol Office at 484-628-8193.

A191901: The GET SET Study (Phase III, Randomized, Therapeutic Trial)

Eligibility: Stg I-III, Hormone Receptor-positive, HER2-Negative breast cancer who have completed chemo/radiation/surgery and recently started or will start Endocrine Therapy (ie. Anastrozole, Tamoxifen, Exemestane, Letrozole etc).

The purpose of this study is to help patients improve endocrine therapy compliance, and assess the best method of improving endocrine therapy compliance (text message reminder, motivational interviewing counseling, a combination of both or enhanced usual care)

Learn more about the A191901 trail or call the Phoenixville Hospital Clinical Research Office at 610-983-1811.

A011801: The CompassHER2 trials (COMprehensive use of Pathologic Response ASSessment to optimize therapy in HER2-positive breast cancer): CompassHER2 Residual Disease (RD), a double-blinded, phase III randomized trial of T-DM1 and placebo compared with T-DM1 and tucatinib.

Learn about the T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial.

Daiichi Sankyo, Inc. / Destiny-05/NSABP B-60: A Phase 3, Multicenter, Randomized, Open-Label, Active-Controlled Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in Subjects with High-Risk HER2-Positive Primary Breast Cancer Who Have Residual Invasive Disease in Breast or Axillary Lymph Nodes Following Neoadjuvant Therapy.

The purpose of this study is to determine if T-DXd would be effective in the treatment of HER2-positive early breast cancer in subjects that have already had treatment prior to breast cancer surgery, specifically for subjects that are considered at high risk for their breast cancer to return.

Learn more about the Destiny-05/NSABP B-60 trial or call the Reading Hospital Protocol Office at 484-628-8193.

ECOG/ACRIN-EA1181: (CompassHER2-pCR): Preoperative THP and postoperative HP in patients who achieve a pathologic complete response.

The purpose of this study is to test whether it is safe to eliminate additional chemotherapy after surgery in patients with HER2-positive breast cancer who have no remaining cancer at surgery, after receiving a single chemotherapy drug (for most patients, paclitaxel), with Herceptin (trastuzumab) and Perjeta (pertuzumab) for 12 weeks before surgery.

Learn more about the ECOG/ACRIN-EA1181 trial or call the Reading Hospital Protocol Office at 484-628-8193.

Johns Hopkins-J15212: Phase II Trial of Palbociclib with Fulvestrant in individuals with hormone receptor-positive, HER2-negative metastatic breast cancer who have progressed on treatment with Palbociclib and an aromatase inhibitor.

The purpose of this study is to look at the role of continuing palbociclib treatment in combination with another type of hormonal therapy after disease progression.

Learn more about the Johns Hopkins- J15212 trial or call the Reading Hospital Protocol office at 484-628-8193.

NRG-CCTG MA.39: A Randomized Trial of Regional Radiotherapy in Biomarker Low-Risk Node-Positive Breast Cancer

The purpose of this study is to compare any good and bad effects of not giving regional radiotherapy to using regional radiotherapy.

Learn more about the NRG-CCTG MA.39 trial or call the Reading Hospital Protocol Office at 484-628-8193.

NSABP B-61 / GO42784: A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared with Physician’s Choice of Adjuvant Endocrine Monotherapy in Patients with Estrogen Receptor–Positive, HER2-Negative Early Breast Cancer.

The purpose of this study is to compare the effects, good or bad, of giredestrant to an approved endocrine therapy (a treatment that blocks or removes hormones), on subjects with ER+,HER2-negative early-stage breast cancer. In this study, the subject will get either giredestrant or a drug chosen specifically for the subject by the study doctor, which may be letrozole, anastrozole, exemestane, or tamoxifen.

Learn more about the NSABP B-61/GO42784 trial or call the Reading Hospital Protocol Office at 484-628-8193.

CK-SAPBI: CyberKnife Stereotactic Accelerated Partial Breast Irradiation Registry

Learn about the CK-SAPBI trail or contact the Pottstown Hospital Clinical Research office at 610-327-7544.